These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21739727)

  • 1. Active surveillance monitoring more stringent in updated NCCN Guidelines for prostate cancer.
    J Natl Compr Canc Netw; 2011 May; 9(5):xxxvii-xlii. PubMed ID: 21739727
    [No Abstract]   [Full Text] [Related]  

  • 2. Critical review: is watchful waiting a viable management option for older men with prostate cancer?
    Bailey DE; Wallace M
    Am J Mens Health; 2007 Mar; 1(1):18-28. PubMed ID: 19482780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active surveillance for early-stage prostate cancer.
    Lancet; 2014 Jan; 383(9913):188. PubMed ID: 24439724
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial comment. ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.
    Bartoletti R; Cai T
    Urology; 2011 Mar; 77(3):e1; author reply e2. PubMed ID: 21376994
    [No Abstract]   [Full Text] [Related]  

  • 5. Acceptance and durability of surveillance as a management choice in men with screen-detected, low-risk prostate cancer: improved outcomes with stringent enrollment criteria.
    Miocinovic R; Jones JS; Pujara AC; Klein EA; Stephenson AJ
    Urology; 2011 Apr; 77(4):980-4. PubMed ID: 21256549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update of the NCCN guidelines for treatment of prostate cancer.
    Millikan R; Logothetis C
    Oncology (Williston Park); 1997 Nov; 11(11A):180-93. PubMed ID: 9430189
    [No Abstract]   [Full Text] [Related]  

  • 7. Further support for active surveillance in the management of low-volume, low-grade prostate cancer.
    Albertsen P
    Eur Urol; 2010 Dec; 58(6):836-7. PubMed ID: 20851512
    [No Abstract]   [Full Text] [Related]  

  • 8. Feasibility of using guidelines to choose treatment for prostate cancer.
    Mohan R; Beydoun H; Davis J; Lance R; Schellhammer P
    Can J Urol; 2010 Feb; 17(1):4975-84. PubMed ID: 20156376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Active surveillance of prostatic cancer].
    Vasarainen H; Ruutu M; Rannikko A
    Duodecim; 2011; 127(6):593-9. PubMed ID: 21528523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors that influence patient enrollment in active surveillance for low-risk prostate cancer.
    Gorin MA; Soloway CT; Eldefrawy A; Soloway MS
    Urology; 2011 Mar; 77(3):588-91. PubMed ID: 21215429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial comment on: tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
    Gallina A
    Eur Urol; 2010 Apr; 57(4):639. PubMed ID: 19299073
    [No Abstract]   [Full Text] [Related]  

  • 12. Editorial comment on: tumor grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
    Yossepowitch O
    Eur Urol; 2010 Apr; 57(4):639-40. PubMed ID: 19299071
    [No Abstract]   [Full Text] [Related]  

  • 13. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment.
    Soloway MS; Soloway CT; Eldefrawy A; Acosta K; Kava B; Manoharan M
    Eur Urol; 2010 Dec; 58(6):831-5. PubMed ID: 20800964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NCCN Practice Guidelines for Prostate Cancer.
    Bahnson RR; Hanks GE; Huben RP; Kantoff P; Kozlowski JM; Kuettel M; Lange PH; Logothetis C; Pow-Sang JM; Roach M; Sandler H; Scardino PT; Taylor RJ; Urban DA; Walsh PC; Wilson TG;
    Oncology (Williston Park); 2000 Nov; 14(11A):111-9. PubMed ID: 11195405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial comment.
    Carroll PR; Whitson JM
    Urology; 2011 Apr; 77(4):984-5. PubMed ID: 21477729
    [No Abstract]   [Full Text] [Related]  

  • 16. Tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
    Ladjevardi S; Sandblom G; Berglund A; Varenhorst E
    Eur Urol; 2010 Apr; 57(4):631-8. PubMed ID: 19299069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer.
    Cooperberg MR; Lin DW; Morgan TM; Chapin BF; Chen RC; Eggener SE
    J Urol; 2022 Feb; 207(2):262-264. PubMed ID: 34775795
    [No Abstract]   [Full Text] [Related]  

  • 18. [Watchful waiting in incidental adenocarcinoma of the prostate].
    Morán Pascual E; Dicapua Sacoto C; Trassierra Villa M; Pontones Moreno JL; Ruiz Cerdá JL; Jiménez Cruz JF
    Actas Urol Esp; 2010 Nov; 34(10):854-9. PubMed ID: 21159280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Active surveillance in prostate cancer. Introduction].
    Briones JR
    Arch Esp Urol; 2014 Jun; 67(5):367-8. PubMed ID: 25039087
    [No Abstract]   [Full Text] [Related]  

  • 20. The feasibility of expectant management with inner-city men with newly diagnosed localized prostate cancer.
    Anai S; Nakamura K; Chang MN; Pendleton J; Yacoub S; Rosser CJ
    J Health Care Poor Underserved; 2008 Feb; 19(1):164-70. PubMed ID: 18263992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.